1

Title: Body mass index changes and their association with SARS-CoV-2 infection: a real-world analysis

Author Names: Jithin Sam Varghese^{1,2}, Yi Guo³, Mohammed K. Ali^{1,2,4}, W. Troy Donahoo⁵, Rosette J. Chakkalakal^{1,2,6}

Author Affiliations:

¹ Emory Global Diabetes Research Center of Woodruff Health Sciences Center and Emory

University, Atlanta, USA.

²Hubert Department of Global Health, Rollins School of Public Health, Emory University,

Atlanta, USA

³Department of Health Outcomes and Biomedical Informatics, College of Medicine, University of Florida, Gainesville, Florida, USA.

⁴Department of Family and Preventive Medicine, School of Medicine, Emory University,

Atlanta, USA

⁵Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, College of

Medicine University of Florida Gainesville FL USA.

6 Department of Medicine, School of Medicine, Emory University, Atlanta, USA

Corresponding Author:

Dr. Rosette J. Chakkalakal, MD, MHS

Mailing address: 49 Jesse Hill Jr. Dr., Room 494, Atlanta, GA 30303

Email: rchakka@emory.edu

Office Phone: 404-778-1641

Sources of Support: National Institutes of Health (R01DK120814-05S1, P30DK111024)

Running title: BMI changes after SARS-CoV-2 infection

Abbreviations: BMI: Body mass index, CP: Computable phenotype, EHR: Electronic health record, HDL: High density lipoprotein, LDL: Low density lipoprotein, PASC: Post-acute sequelae of COVID-19, T2DM: Type 2 diabetes

Funding: This research was supported by the National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health, award number 3R01DK120814- 05S1. MKA was partially supported by the Georgia Center for Diabetes Translation Research which is funded by the National Institutes of Health (P30DK111024).

Conflicts of Interest: The authors declare no competing financial interests.

3

ABSTRACT

Objective:

To study body mass index (BMI) changes among individuals aged 18-99 years with and without SARS-CoV-2 infection.

Subjects/Methods:

Using real-world data from the OneFlorida+ Clinical Research Network of the National Patient-Centered Clinical Research Network, we compared changes over time in BMI in an Exposed cohort (positive SARS-CoV-2 test between March 2020 - January 2022), to a contemporary Unexposed cohort (negative SARS-CoV-2 tests), and an age/sex-matched Historical control cohort (March 2018 - January 2020). Body mass index (kg/m²) was retrieved from objective measures of height and weight in electronic health records. We used target trial approaches to estimate BMI at baseline and change per 100 days of follow-up for Unexposed and Historical cohorts relative to the Exposed cohort by categories of sex, race-ethnicity, age, and hospitalization status.

Results:

The study sample consisted of 44,436 (Exposed cohort), 164,118 (Unexposed cohort), and 41,189 (Historical cohort). Cumulatively, 62% were women, 21.5% Non-Hispanic Black, 21.4% Hispanic and 5.6% Non-Hispanic Other. Patients had an average age of 51.9 years (SD: 18.9). At baseline, relative to the Exposed cohort (mean BMI: 29.3 kg/m^2 [95%CI: 29.0, 29.7]), the Unexposed $(-0.07 \text{ kg/m}^2 [95\% \text{CI}; -0.12, -0.01])$ and Historical controls $(-0.27 \text{ kg/m}^2 [95\% \text{CI}; -0.12, -0.01])$ 0.34, -0.20]) had lower BMI. Relative to no change in the Exposed over 100 days (0.00 kg/m² [95%CI; -0.03,0.03]), the BMI of those Unexposed decreased (-0.04 kg/m^2) [95%CI; -0.06, -0.01]) while the Historical cohort's BMI increased $(+0.03 \text{ kg/m}^2[95\%CI; 0.00, 0.06])$. BMI changes were consistent between Exposed and Unexposed cohorts for most population groups, except at start of follow-up period among Males and those 65 years or older, and in changes over 100 days among Males and Hispanics.

Conclusions:

4

In a diverse real-world cohort of adults, mean BMI of those with and without SARS-CoV2 infection varied in their trajectories. The mechanisms and implications of weight retention following SARS-CoV-2 infection remain unclear.

5

1 **Introduction**

16 The purpose of this real-world evidence study was to characterize key changes in BMI 17 among individuals who survived the acute phase (defined as the first 30 days) of SARS-CoV-2 18 infection in a socio-demographically diverse cohort and compare them with a contemporary 19 cohort who always tested negative for SARS-CoV-2 as well as a historical cohort (prior to the 20 pandemic) matched on age and sex to those who tested positive. Using analytical approaches for 21 target trial emulation, we examined if BMI changes differed by socio-demographic (sex, race-22 ethnicity, age) category and hospitalization status.

23 **Methods**

6

24 *Study Design*

43 using Observational Routinely-collected health Data (RECORD) Statement.¹⁷

44 *Exposure Cohorts*

7

45 The Exposed cohort were individuals exposed to SARS-CoV-2, defined by meeting at 46 least one of two criteria between 1 March 2020 and 29 January 2022: any positive test (Nucleic 47 Acid Amplification Tests [NAAT] or antigen) or COVID-19 related ICD-10-CM codes (E08 to 48 E13).¹³ The index date of infection exposure (T_0) was defined as the date of the first positive test 49 or date of record for the ICD-10-CM code. The timeline for cohort selection and follow-up is 50 presented in **Supplementary Figure 1**.

51 The Unexposed cohort were individuals not measured to have had exposure to SARS-52 CoV-2 and consisted of individuals who met all of three criteria between 1 March 2020 and 29 53 January 2022: at least one negative test (NAAT or antigen), no COVID-19 related International 54 Classification of Diseases-10 CM (ICD-10 CM) codes (E08.X to E13.X), and no positive test 55 during follow-up period. Since the Unexposed cohort tested negative throughout the follow-up 56 period, to maximize follow-up duration, the index date (T_0) was defined as the date of the first 57 negative test.

58 The Historical cohort was constructed to be representative of typical clinic visits among 59 patients who utilized the healthcare delivery systems in the pre-pandemic period, and ensure 60 differences observed in the Exposed and Unexposed cohorts were not due to the pandemic 61 period. Patients who were not subsequently part of Exposed or Unexposed cohorts were sampled 62 into the Historical cohort after matching on sex and 5-year age intervals. The index dates of 63 Historical cohort ranged from 2 March 2018 and 30 January 2020, and were selected such that 64 the last date of possible follow-up (29 February 2020) did not overlap with the start of the 65 calendar period of identification (1 March 2020) for the Exposed and Unexposed cohorts.

66 We restricted our study sample to individuals who had at least one measurement of 67 weight in the year preceding their observation period in our study (**Supplementary Figure 2**).

8

68 The final analytic sample consisted of 44,436 Exposed, 164,118 Unexposed controls and 41,189 69 Historical controls. All subsequent analysis accounted for the stratified sampling of Historical 70 controls.

71 *Outcomes – Cardiometabolic Health Indicators*

72 We explored average longitudinal change in body mass index (BMI) based on objective 73 measures recorded in the EHR. Follow-up period (in days) was calculated as number of days 74 from 30 days after index date (i.e. Time $_{\text{tF}} = t - [T_0 + 30]$), defined as the post-acute phase of the 75 disease. To exclude weight changes associated with severe illness and weight loss prior to 76 mortality, we included only those participants who were alive at least 30 days after SARS-CoV2 77 infection was detected.^{2,13}

78 *Effect Modifiers – Socio-demographic Characteristics and Hospitalization Status*

79 Socio-demographic characteristics included sex (male, female), race-ethnicity (Non-

80 Hispanic White, Non-Hispanic Black, Hispanic), and age at index date (18-39 years, 40-64 years,

81 65 years and older). We determined all-cause hospitalization status (not hospitalized,

82 hospitalized) based on the clinical encounter coded on the index date.

83 *Confounders*

84 We used a combination of biologically plausible covariates and empirically identified 85 covariates to adjust for baseline differences between cohorts using inverse probability weighting 86 (IPW) (see **Supplementary Methods**). Biologically plausible covariates known to be associated 87 with higher cardiometabolic risk were derived from data collected before the index date. We 88 used data collected within 1 year of index date to define smoking status (yes/no), use of 89 medications relevant to cardiometabolic health (yes/no; antihypertensives, statins,

9

110 *Statistical Analysis*

111 We present an overview of the analytic strategy in **Supplementary Figure 3**.

10

112 *Inverse probability weighting for cohort membership and follow-up*

113 Since this is an observational study, baseline characteristics may differ between exposed, 114 unexposed, and historical control cohorts resulting in non-random cohort membership. To 115 minimize instrumental variable bias when constructing propensity scores, we performed variable 116 selection of empirically identified covariates longitudinally associated with BMI after adjusting 117 for multiple comparison correction using the Benjamini-Hochberg procedure. Next, random 118 forests models for probability of membership in each exposure cohort, relative to other cohorts, 119 were fit separately with 5-fold cross-validation. We tuned the parameters based on the area under 120 receiver operating characteristic curve (AUC) and identified 2000 trees and 10 observations per 121 node as the best combination of hyperparameters. We included both biologically-plausible and 122 algorithmically selected covariates to estimate the high-dimensional propensity score.^{19,20} We 123 assessed covariate balance between the Unexposed and Historical Control cohorts, relative to the 124 Exposed, after IPW using population standardized bias.²¹ Population standardized bias is the 125 maximum difference between IP weighted group mean and unweighted pooled mean.²¹ Bias less 126 than 0.1 after weighting was considered as indicative of covariate balance.

127 We additionally constructed IPW for availability of follow-up data for BMI to minimize 128 selection bias, since not all participants had data on all cardiometabolic health indicators during 129 the follow-up period.²² The final weight for each individual in the analytic sample is a product of 130 treatment weights and selection weights. We provide additional detail of the modeling strategy in 131 an extended methodological note (**Supplementary Methods)**.

132 IPW were also constructed separately for each socio-demographic, clinical, and 133 community characteristic of interest with numerator reflecting probability of cohort membership

11

134 under levels of each characteristic (sex, race-ethnicity, age) when assessing differences between 135 l evels.²³

136 *Changes in BMI*

137 First, we modeled BMI in the follow-up period for Exposed, Unexposed, and Historical 138 Control cohorts using marginal structural models. We used a difference-in-differences 139 framework to understand if changes in BMI per 100 days of follow-up differed for Unexposed 140 and Historical cohorts relative to the Exposed cohort. We adjusted for all imbalanced 141 characteristics except laboratory parameters in the regression model since the latter had high 142 rates of missingness. Second, we estimated average BMI at origin date and longitudinal change 143 in BMI per 100 days of follow-up across categories of sex (male vs female), race-ethnicity (NH 144 White vs NH Black vs Hispanic), age (18-39 vs 40-64 vs 65 and older) and hospitalization status 145 by exposure group. We did not adjust for multiple comparisons in these prespecified subgroup 146 analysis.

147 *Sensitivity Analysis*

148 First, to minimize the influence of patients who rarely used the health system, we 149 restricted the analytic sample to those patients with at least 100 days of follow-up and at least 150 two encounters where BMI was measured in the follow-up period. Second, to account for 151 differences in health outcomes due to differences in reasons for visit during follow-up period, we 152 adjusted for number and types of clinical encounters between measurements of the 153 cardiometabolic risk factors as a time-varying covariate. Third, to account for differences in 154 timing of follow-up visits, we adjusted for COVID-19 transmission in county of residence on 155 dates when cardiometabolic risk factors were measured. COVID-19 cases and test positivity per

12

13

200 kg/m², 95%CI: -0.34, -0.20) cohorts. Change in BMI per 100 days of follow-up was null for the

14

206 Adjusted differences in BMI at origin date for subgroups of sex, age, race-ethnicity, and 207 hospitalization status are presented in **Figure 1A**. Across most socio-demographic subgroups 208 (except among adult Males, those aged 65 and older, Hispanic adults, non-hospitalized adults) 209 BMI at origin date was higher among Exposed, relative to Unexposed and Historical cohorts 210 (**Supplementary Table 5**). Relative to Exposed cohort (**Figure 1B**), the change in BMI per 100 211 days of follow-up among the Unexposed cohort was lower among Males (difference-in-212 differences [DiD]: -0.07 kg/m^2 , 95% CI: -0.12 , -0.02) and non-Hospitalized adults (DiD: -0.04 213 kg/m², 95%CI: -0.07, -0.01). Relative to the Exposed cohort, the change in BMI per 100 days of 214 follow-up among the Historical cohort was higher among Females (DiD: 0.07 kg/m^2 , 95%CI: 215 0.03, 0.11), Non-Hispanic White adults (DiD: 0.07 kg/m², 95%CI: 0.03, 0.11) and non-216 Hospitalized adults (DiD: 0.03 kg/m^2 , $95\% \text{CI}$: $0.00, 0.06$)

217 Results were similar when restricting to those with at least 100 days of follow-up and at 218 least two encounters when BMI was measured (**Supplementary Table 6**), after adjusting for 219 number and types of encounters between BMI measurements (**Supplementary Table 7**) and 220 after adjusting for COVID-19 cases and testing (**Supplementary Table 8**). Results were also 221 similar after accounting for missing data in laboratory parameters using multiple imputation 222 **(Supplementary Table 9**).

223 **Discussion**

15

16

247 of T2DM, who were users of the healthcare system before the pandemic, and who were tested for 248 SARS-CoV-2. We additionally included a historical control cohort, matched on age and sex, to 249 characterize differences in the patient population attributable to the pandemic. The OneFlorida+ 250 Data Trust is a part of the National Patient-Centered Clinical Research Network (PCORnet) and 251 follows the common data model, facilitating reproducibility. Compared to other real-world 252 studies, the analytic sample was younger and more diverse across categories of race-ethnicity, 253 age, and sex.^{2,5} The duration of follow-up was longer than other studies reporting post-acute 254 sequelae of COVID-19.^{3,5,6,13} We used methods for target trial emulation to minimize 255 confounding, including minimizing the potential for instrumental variable bias in high 256 dimensional confounder selection.

257 There are several limitations for this study. First, the OneFlorida+ CRN includes data 258 from many but not all of Florida's healthcare providers; our analyses could not account for 259 patients testing positive at centers not participating in the OneFlorida+ CRN. However, the 260 criteria we used for the lookback period were meant to identify regular users of healthcare 261 systems participating in OneFlorida+.³⁰ Additionally, our sample selection was not biased by 262 home testing because it became widespread only after the last date of follow-up in February 263 2022. Second, although we used a high dimensional propensity score for confounding 264 adjustment, we cannot rule out all differences in clinical characteristics at the time of the index 265 encounter. For instance, those Exposed and Unexposed may have had different reasons for 266 seeking care. Finally, singly-robust machine learning based propensity scores are inferior to 267 doubly-robust methods for lower bias and confidence-interval coverage.³¹ However, to our 268 knowledge, there were no standard software packages to implement doubly-robust causal 269 inference methods for sparse, longitudinal datasets such as electronic health records.

17

279

18

ACKNOWLEDGEMENT/SUPPORT

Acknowledgements: This research was supported by the National Institute for Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health, award number 3R01DK120814-05S1. MKA was partially supported by the Georgia Center for Diabetes Translation Research which is funded by the National Institutes of Health (P30DK111024). The authors thank the OneFlorida+ Data Trust team (Kathryn Shaw, Meggen Kaufman, Jiang Bian, Elizabeth Shenkman) for support on query development and data extraction. The authors thank Shihab Chowdhury for administrative support.

Author contributions: RJC, WTD and JSV conceptualized the study with inputs from MKA and YG. JSV conducted the analysis. JSV wrote the first draft with inputs from RJC. All authors reviewed and edited subsequent drafts.

Competing Interest: The authors declare no competing financial interests.

Data availability statement: The code for the analysis is available on https://github.com/jvargh7/pasc_cardiometabolic_risk. Information of the OneFlorida+ CRN is provided at https://onefloridaconsortium.org/, and OneFlorida+ data are made available to researchers with an approved study protocol at https://onefloridaconsortium.org/front-door/prepto-research-data-query/. For questions regarding OneFlorida+, email: OneFloridaOperations@health.ufl.edu.

References

- 1. Singh AK, Khunti K. COVID-19 and Diabetes. *Annu Rev Med*. 2022;73(1):129-147. doi:10.1146/annurev-med-042220-011857
- 2. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long COVID: a cohort study. *The Lancet Diabetes & Endocrinology*. 2022;10(5):311-321. doi:10.1016/S2213-8587(22)00044-4
- 3. Barrett CE, Koyama AK, Alvarez P, et al. Risk for Newly Diagnosed Diabetes >30 Days After SARS-CoV-2 Infection Among Persons Aged <18 Years — United States, March 1, 2020–June 28, 2021. *MMWR Morb Mortal Wkly Rep*. 2022;71(2):59-65. doi:10.15585/mmwr.mm7102e2
- 4. Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19. *Diabetologia*. Published online March 16, 2022. doi:10.1007/s00125-022-05670-0
- 5. Holman N, Barron E, Young B, et al. Comparative Incidence of Diabetes Following Hospital Admission for COVID-19 and Pneumonia: A Cohort Study. *Diabetes Care*. 2023;46(5):938- 943. doi:10.2337/dc22-0670
- 6. Al-Aly Z, Xie Y, Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. *Nature*. 2021;594(7862):259-264. doi:10.1038/s41586-021-03553-9
- 7. Xu E, Xie Y, Al-Aly Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. *The Lancet Diabetes & Endocrinology*. 2023;11(2):120-128. doi:10.1016/S2213- 8587(22)00355-2
- 8. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. *Nat Med*. 2022;28(3):583-590. doi:10.1038/s41591-022-01689-3
- 9. Mude W, Oguoma VM, Nyanhanda T, Mwanri L, Njue C. Racial disparities in COVID-19 pandemic cases, hospitalisations, and deaths: A systematic review and meta-analysis. *J Glob Health*. 2021;11:05015. doi:10.7189/jogh.11.05015
- 10. Dalsania AK, Fastiggi MJ, Kahlam A, et al. The Relationship Between Social Determinants of Health and Racial Disparities in COVID-19 Mortality. *J Racial and Ethnic Health Disparities*. 2022;9(1):288-295. doi:10.1007/s40615-020-00952-y
- 11. Beckles GL, Chou CF. Disparities in the Prevalence of Diagnosed Diabetes United States, 1999–2002 and 2011–2014. *MMWR Morb Mortal Wkly Rep*. 2016;65(45):1265-1269. doi:10.15585/mmwr.mm6545a4
- 12. Hogan WR, Shenkman EA, Robinson T, et al. The OneFlorida Data Trust: a centralized, translational research data infrastructure of statewide scope. *Journal of the American Medical Informatics Association*. 2022;29(4):686-693. doi:10.1093/jamia/ocab221

- 13. Zhang H, Zang C, Xu Z, et al. Data-driven identification of post-acute SARS-CoV-2 infection subphenotypes. *Nat Med*. 2023;29(1):226-235. doi:10.1038/s41591-022-02116-3
- 14. Hernandez-Romieu AC, Carton TW, Saydah S, et al. Prevalence of Select New Symptoms and Conditions Among Persons Aged Younger Than 20 Years and 20 Years or Older at 31 to 150 Days After Testing Positive or Negative for SARS-CoV-2. *JAMA Netw Open*. 2022;5(2):e2147053. doi:10.1001/jamanetworkopen.2021.47053
- 15. PCORnet. Common Data Model (CDM) Specification, Version 6.0. Published online January 2022. https://pcornet.org/wp-content/uploads/2022/01/PCORnet-Common-Data-Model-v60- 2020_10_221.pdf
- 16. Wiese AD, Roumie CL, Buse JB, et al. Performance of a computable phenotype for identification of patients with diabetes within PCORnet: The Patient□Centered Clinical
Research Network, *Pharmacoenidemial Drug Saf.* 2019;28(5):632-639, doi:10,1002/pds Research Network. *Pharmacoepidemiol Drug Saf*. 2019;28(5):632-639. doi:10.1002/pds.4718
- 17. Benchimol EI, Smeeth L, Guttmann A, et al. The REporting of studies Conducted using Observational Routinely-collected health Data (RECORD) Statement. *PLoS Med*. 2015;12(10):e1001885. doi:10.1371/journal.pmed.1001885
- 18. Rassen JA, Blin P, Kloss S, et al. High□dimensional propensity scores for empirical covariate selection in secondary database studies: Planning, implementation, and reported covariate selection in secondary database studies: Planning, implementation, and reporting. *Pharmacoepidemiology and Drug*. 2023;32(2):93-106. doi:10.1002/pds.5566
- 19. Tian Y, Schuemie MJ, Suchard MA. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. *International Journal of Epidemiology*. 2018;47(6):2005-2014. doi:10.1093/ije/dyy120
- 20. Simon N, Friedman J, Hastie T. A Blockwise Descent Algorithm for Group-penalized Multiresponse and Multinomial Regression. Published online 2013. doi:10.48550/ARXIV.1311.6529
- 21. McCaffrey DF, Griffin BA, Almirall D, Slaughter ME, Ramchand R, Burgette LF. A tutorial on propensity score estimation for multiple treatments using generalized boosted models. *Statist Med*. 2013;32(19):3388-3414. doi:10.1002/sim.5753
- 22. Weuve J, Tchetgen Tchetgen EJ, Glymour MM, et al. Accounting for Bias Due to Selective Attrition: The Example of Smoking and Cognitive Decline. *Epidemiology*. 2012;23(1):119- 128. doi:10.1097/EDE.0b013e318230e861
- 23. Robins JM, Hernán MÁ, Brumback B. Marginal Structural Models and Causal Inference in Epidemiology: *Epidemiology*. 2000;11(5):550-560. doi:10.1097/00001648-200009000-00011
- 24. Gao M, Piernas C, Astbury NM, et al. Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study. *The Lancet Diabetes & Endocrinology*. 2021;9(6):350-359. doi:10.1016/S2213- 8587(21)00089-9

- 25. Kompaniyets L, Goodman AB, Belay B, et al. Body Mass Index and Risk for COVID-19– Related Hospitalization, Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death — United States, March–December 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(10):355-361. doi:10.15585/mmwr.mm7010e4
- 26. Anderson LN, Yoshida \Box Montezuma Y, Dewart N, et al. Obesity and weight change during the COVID \Box 19 pandemic in children and adults: A systematic review and meta \Box analysis the COVID \Box 19 pandemic in children and adults: A systematic review and meta \Box analysis.
Obesity Reviews 2023:24(5):213550, doi:10.1111/obr.13550. *Obesity Reviews*. 2023;24(5):e13550. doi:10.1111/obr.13550
- 27. Lin AL, Vittinghoff E, Olgin JE, Pletcher MJ, Marcus GM. Body Weight Changes During Pandemic-Related Shelter-in-Place in a Longitudinal Cohort Study. *JAMA Netw Open*. 2021;4(3):e212536. doi:10.1001/jamanetworkopen.2021.2536
- 28. Perakakis N, Harb H, Hale BG, et al. Mechanisms and clinical relevance of the bidirectional relationship of viral infections with metabolic diseases. *The Lancet Diabetes & Endocrinology*. 2023;11(9):675-693. doi:10.1016/S2213-8587(23)00154-7
- 29. Harding JL, Oviedo SA, Ali MK, et al. The bidirectional association between diabetes and long-COVID-19 - A systematic review. *Diabetes Res Clin Pract*. 2023;195:110202. doi:10.1016/j.diabres.2022.110202
- 30. Haneuse S, Arterburn D, Daniels MJ. Assessing Missing Data Assumptions in EHR-Based Studies: A Complex and Underappreciated Task. *JAMA Netw Open*. 2021;4(2):e210184. doi:10.1001/jamanetworkopen.2021.0184
- 31. Naimi AI, Mishler AE, Kennedy EH. Challenges in Obtaining Valid Causal Effect Estimates With Machine Learning Algorithms. *American Journal of Epidemiology*. 2023;192(9):1536- 1544. doi:10.1093/aje/kwab201

Table 1. Socio-demographic, clinical and community characteristics of exposure cohorts before weighting and population standardized bias after weighting.

Medication and Comorbidities were imputed as 'No' if data were not found in PRESCRIBING and DIAGNOSIS datasets. Hospitalization within 30 days of index date was 'Yes' if any encounter of type emergency department to inpatient (ED), inpatient (IP), non-acute institutional stay (IS) and observation stay (OS). All others were coded as 'No'.

Values were Mean (standard deviation) or median $(25th$ percentile, $75th$ percentile) or frequency (percentage%)

a Population standardized bias was computed after inverse probability weighting. Descriptive statistics after weighting is provided in **Supplementary Table 2**. Population standardized bias less than 0.1 after weighting is considered as indicative of covariate balance. Values greater than or equal to 0.1 are bolded.

Table 2. Marginal estimates at origin date and change at 100 days of follow-up for body mass index

All estimates are from the marginal structural model with statistical interaction of exposure group, socio-demographic characteristic (i.e., sex, age, race-ethnicity) and time, after inverse probability weighting for confounding and loss to follow-up. Associations are adjusted for BMI within last 1 year of lookback period and imbalanced covariates.

Figure 1 Legend

Our historical cohort corresponds with the blue lines. Our unexposed cohort corresponds with the

green lines. Our exposed cohort corresponds with the red lines.

All estimates are from the marginal structural model with statistical interaction of exposure group, effect modifier (i.e., sex, age, race-ethnicity, hospitalization status) and time. Associations are adjusted for BMI closest to index date during lookback period and any imbalanced covariates. Associations reported above are also available in **Supplementary Table 5**.

Panel A: Difference relative to Exposed cohort at start of follow-up. Panel B: Difference relative to Exposed cohort per 100 days of follow-up.